Abstract: A low-molecular-weight water-soluble elastin having a molecular weight of about 10,000 to 30,000 and a high-molecular-weight water-soluble elastin having a molecular weight of about 30,000 to 300,000 are provided, 79% to 84% of the constituent amino acids of the elastin comprising proline, glycine, alanine, and valine, 2% to 3% comprising aspartic acid and glutamic acid, 0.7% to 1.3% comprising lysine, histidine, and arginine, and 0.2% to 0.4% comprising desmosine and isodesmosine. The low-molecular-weight water-soluble elastin that is obtained may be used in a functional food or a medicine. Such a high-purity water-soluble elastin may be produced by obtaining pure insoluble elastin by subjecting animal body tissue to a collagen removal treatment and then fragmenting the insoluble elastin by means of a solubilizing liquid. It may be produced simply, merely by adjusting the concentration of an alkaline solution and the reaction time without recovering insoluble elastin from the animal body tissue.

Abstract: The present invention provides methods and compositions for regulating gene expression using transcription factors linked to proteins that localize to the transcriptional machinery.

Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Abstract: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Abstract: Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin ?4, an isoform of Thymosin ?4 or oxidized Thymosin ?4.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.

Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.

Abstract: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.

Abstract: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.

Abstract: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.

Abstract: A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.

Abstract: The present invention concerns the isolation of phlorizin from plants of the genus Lithocarpus, phlorizin-containing compositions and their uses.

Abstract: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

Abstract: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants to a host in need thereof. The present also includes a novel method for simultaneously inhibiting expression of pro-inflammatory cytokines, preventing ROS generation and augmenting anti-oxidant defenses. The activity of this composition is conducive to ultimately preserving cognitive function and providing a level of neuroprotection.

Abstract: 15-fluoroketolides of the formula having improved activity and safety, compositions comprising them, and methods for their preparation and use in the treatment of bacterial infections.

Abstract: A compound of formula (I) For use as antibacterial agents, compositions containing same, processes for their preparation and their use in therapy.

Abstract: The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a dibenzo[e,h]azulene subunit with anti-inflammatory, analgesic and/or antipyretic activity and L represents a linking group covalently linking M and D; (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals.

Abstract: A stabilized azithromycin composition comprising azithromycin monohydrate, and about 5 to about 15 weight percent, based on the total weight of the composition, of water. The present inventors have unexpectedly determined that a certain amount of water is necessary to stabilize a pharmaceutical composition comprising azithromycin monohydrate. In addition, the stabilized azithromycin monohydrate compositions do not require an antioxidant.

Abstract: An improved method for using a NNRTI in the treatment of HIV-1 infection, comprising administering to a human, needing treatment for HIV-1 infection, a therapeutically effective amount of said NNRTI or a pharmaceutically acceptable salt thereof, and an amount of an inhibitor of the cytochromes P450 that is sufficient to elevate, enhance, or extend plasma concentrations of said NNRTI.

Abstract: There are provided a polypeptide specific to liver cancer, a polynucleotide coding for the polypeptide, and an RNA molecule suppressing the expression of the polypeptide. The present invention is particularly intended for a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; a polypeptide having at least 80% homology to the amino acid sequence of SEQ ID NO: 1 and having immunogenicity inducing the production of an antibody against the polypeptide comprising the amino acid sequence of SEQ ID NO: 1; nucleotide fragments thereof; polynucleotides coding for the polypeptides and fragments thereof; and an RNA molecule having a partial sequence corresponding to mRNA coding for the polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

Abstract: Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.

Abstract: Inhibitory oligonucleotides are disclosed which are targeted to three specific target regions and subsequences of the target regions found on nucleic acids encoding Bcl-2. These inhibitory oligonucleotides are generally of from about 8 to about 50 nucleotides in length. Specific preferred oligonucleotides are disclosed. The oligonucleotides of the invention may be incorporated into compositions such as pharmaceutical compositions, and may be used in methods for inhibiting the expression of Bcl-2 in a cell or tissue, methods for treating conditions susceptible to modulation of Bcl-2 expression in an organism, and methods for detecting nucleic acid encoding BCL-2.

Abstract: The invention relates to methods for the identification of novel receptors and/or novel ligands. The invention is based on the concept that parasites have developed a number of biologically active compounds in their saliva to cope with the defense mechanisms of the host organisms on which they feed and to manipulate the biological functions of host molecules to their advantage. These saliva compounds can be used to identify novel molecules within the host systems. Furthermore, these saliva compounds can be used to elucidate the functions of molecules whose existence is already known.

Abstract: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.

Abstract: Presently described is a guanosine-rich polynucleotide molecule with therapeutic utility for treating or preventing the growth of cancerous cells. In addition, a method of retarding cell cycle progression and inducing apoptosis in tumor cells using synthetic oligonucleotides is also described.

Abstract: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.

Abstract: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gfRas mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.

Abstract: The invention provides methods of treating and preventing heat shock protein-associated diseases and conditions.

Abstract: The present invention relates to raw materials for pharmaceuticals and the like, wherein the raw materials can be effective in preventing and remedying various lifestyle-related diseases such as obesity and hyperlipidemia, safe, and applicable in wide areas; and the present invention also relates to a preventive/remedy for obesity, an agent for suppressing fat accumulation in internal organs, an agent for suppressing blood glucose level increase, an agent for suppressing blood insulin level increase, an agent for preventing and remedying diabetes, an agent for improving lipid metabolism, and an agent for promoting fatty acid oxidation, wherein waxy corn starch is an active ingredient.

Abstract: The present invention provides compounds of formula I: (I) along with methods of making the same, compositions thereof, and methods of use thereof, particularly methods of use as fungicides.

Abstract: The present invention is directed to a compound of Formula (I): or an enantiomer, diastereomer, polymorph or pharmaceutically acceptable salt thereof and methods for preparing said compounds and compositions, intermediates and derivatives thereof, and methods for treating inflammatory or serine protease mediated disorders.

Abstract: Autoimmune disease therapy in a patient treated with apoptosis-inducing agents is enhanced by co-administration of sphingomyelin. The combination most likely enhances an autoimmune disease cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. In alternative embodiments, sphingomyelin may be administered alone, in combination with corticosteroids, and/or in combination with a apoptosis-inducing agent.

Abstract: A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is a neutral or negatively charged N- or S-donor ligand; Y is a counterion; in is 0 or 1; q is 1, 2 or 3; C? is C1-12 alkylene bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are each independently O-donor, N-donor or S-donor ligands, and may be connected to one another. The compounds are used in cancer therapy.

Abstract: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or tetraplegic individuals.

Abstract: The present invention is directed to substituted N-aryl-9-oxo-9H-fluorene-1-carboxamides and analogs thereof, represented by the general Formula I: (I) wherein R1-R8, X and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

Abstract: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.

Abstract: Methods for inhibiting the production of TSST-1 from Gram positive bacteria are disclosed. The methods comprise exposing the Gram positive bacteria to compounds capable of inhibiting the production of TSST-1 from the Gram positive bacteria.

Abstract: This invention discloses (20S)-1?-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat immune disorders in humans as well as renal osteodystrophy.

Abstract: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of rimexolone to penetrate the cornea, a high portion of the drug remains on the surface of the eye, which is the primary locus of the inflammatory conditions associated with dry eye. This enables a very low concentration of drug to be utilized, which in turn reduces the potential for elevations of intraocular pressure and cataract formation.

Abstract: A composition comprising: a) a primary lipid component obtainable as the reaction product of one or more carboxylic acids with at least one of glycerol and propylene glycol; b) a co-lipid component selected from at least one of phosphorus-containing lipids and hydroxylated carboxylic acid esters of mono- and di-glycerides; c) lipophilic physiologically active ingredient; and d) water. The composition may be used to improve the bioavailability of the lipophilic physiologically active ingredient in food or beverage products. The physiologically active ingredient may be selected from carotenoids, fat-soluble vitamins, phytosterols, phytostanols and combinations thereof.

Abstract: The present invention provides novel compositions and methods for repair and regeneration of tissues or organs of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat or prevent gastrointestinal cancer such as colorectal carcinoma, stomach cancer and esophagus cancer. The composition is in an oral dosage form and comprises edible oil homogenized with a sterol compound at a concentration of at least 0.5% by weight and edible wax at a concentration ranging from 3% to 30% by weight.

Abstract: The present invention is related to an oxime of the 13?-ethyl-17?-hydroxi-18,19-dinorpregn-4-en-20-in-3-o (norelgestromin) of Formula I with a relation of isomers E/Z between 1.3 and 1.6 and the method of producing the oxime.

Abstract: Fermentation of a nutrient medium with a Nocardia spp. yields a novel broad spectrum antibiotic compound of structural formula (I) or a pharmaceutically acceptable salt, ester, enantiomer, diasteriomer or mixture.

Abstract: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.

Abstract: A method of stabilizing pharmaceutical compositions containing cefovecin sodium salt which is in an amorphous or other disordered state is disclosed.

Abstract: This invention relates to CXCR4 inhibitors and their use in treating and/or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.

Abstract: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

Abstract: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.